Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal hydrogels, previously announced the ...

Polyrizon (PLRZ) previously announced the initiation of preclinical studies for intranasal Naloxone, a life-saving opioid overdose treatment.

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...

The study will be conducted in collaboration with Professor Fabio Sonvico, Associate Professor at the Department of Food and Drug of the University of Parma (Italy) a leading expert in the development ...

Polyrizon's filing of its Annual Report on Form 20-F with the SEC reflects compliance with regulatory requirements, which can enhance the company's credibility and transparency to investors.

Raanana, Israel, March 10, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative ...

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech firm with a market capitalization of $3.46 million focused on developing nasal hydrogels, has launched preclinical studies for ...

Polyrizon Ltd., a biotech company based in Raanana, Israel, has announced the start of preclinical studies for its intranasal Naloxone product aimed at treating opioid overdoses. Collaborating ...

RAANANA, Israel - Polyrizon Ltd. (NASDAQ:PLRZ), a micro-cap biotech firm with a market capitalization of $3.46 million focused on developing nasal hydrogels, has launched preclinical studies for an ...